Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ADGM
stocks logo

ADGM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Adagio Medical Holdings Inc (ADGM.O) is -0.88, compared to its 5-year average forward P/E of -0.04. For a more detailed relative valuation and DCF analysis to assess Adagio Medical Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.04
Current PE
-0.88
Overvalued PE
0.15
Undervalued PE
-0.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.25
Undervalued EV/EBITDA
-0.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1972.62% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ADGM News & Events

Events Timeline

(ET)
2025-11-12
16:12:20
Adagio Medical announces Q3 earnings per share of 66 cents, compared to a loss of $8.34 in the same period last year.
select
2025-10-10 (ET)
2025-10-10
15:42:08
Adagio Medical reveals initial acute findings from the FULCRUM-VT study
select
2025-10-01 (ET)
2025-10-01
08:14:38
Adagio Medical finishes participant enrollment for FULCRUM-VT trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
10-11Newsfilter
Adagio Medical Presents Initial Acute Findings from FULCRUM-VT U.S. Pivotal Study During Late Breaking Session at VT Symposium

  • Study Results: Adagio Medical's FULCRUM-VT Study reported a 97.4% acute success rate for Ultralow Temperature Cryoablation (ULTC) in treating Sustained Monomorphic Ventricular Tachycardia (SMVT) among 207 patients, with a 2.5% rate of major adverse events.

  • Future Implications: The promising preliminary results suggest that ULTC could transform treatment for ventricular tachycardia, with long-term outcomes and further effectiveness analysis expected to be shared at future conferences.

[object Object]
Preview
5.0
09-08NASDAQ.COM
Deborah Kaster, Chief Business Officer of Adagio Medical, Takes On Additional Role as CFO

  • Leadership Change at Adagio Medical: Deborah Kaster has been appointed as Chief Financial Officer in addition to her role as Chief Business Officer, effective September 5, 2025, succeeding Dan George.

  • Kaster's Background: Kaster joined Adagio Medical in March 2025 and has extensive experience in investor relations and business development, having previously worked at Shockwave Medical, Gilmartin Group, and Kyphon.

[object Object]
Preview
2.0
04-22TipRanks
3 Penny Stocks to Watch Now, 4/22/25

  • Penny Stocks to Watch: Adagio Medical, China SXT Pharmaceuticals, and Motorsport Games are highlighted as penny stocks to monitor on April 22, 2025, based on their high Dollar Volume despite recent stock price declines.

  • Company Highlights: Adagio Medical focuses on cardiac arrhythmia treatments and received FDA recognition; China SXT Pharmaceuticals faced a significant drop amid market issues; Motorsport Games regained Nasdaq compliance but also saw a stock price decrease.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Adagio Medical Holdings Inc (ADGM) stock price today?

The current price of ADGM is 0.8906 USD — it has decreased -2.94 % in the last trading day.

arrow icon

What is Adagio Medical Holdings Inc (ADGM)'s business?

Adagio Medical Holdings, Inc. is a commercial stage medical device company. It is focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia. It is developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for the treatment of ventricular arrhythmia.

arrow icon

What is the price predicton of ADGM Stock?

Wall Street analysts forecast ADGM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADGM is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Adagio Medical Holdings Inc (ADGM)'s revenue for the last quarter?

Adagio Medical Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Adagio Medical Holdings Inc (ADGM)'s earnings per share (EPS) for the last quarter?

Adagio Medical Holdings Inc. EPS for the last quarter amounts to -0.66 USD, increased 106.25 % YoY.

arrow icon

What changes have occurred in the market's expectations for Adagio Medical Holdings Inc (ADGM)'s fundamentals?

The market is revising No Change the revenue expectations for ADGM for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -43.63%.
arrow icon

How many employees does Adagio Medical Holdings Inc (ADGM). have?

Adagio Medical Holdings Inc (ADGM) has 86 emplpoyees as of December 05 2025.

arrow icon

What is Adagio Medical Holdings Inc (ADGM) market cap?

Today ADGM has the market capitalization of 18.86M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free